A Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (LYNK-002)
A Phase II Study of Olaparib Monotherapy in Participants with Previously Treated, HomologousRecombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (LYNK-002)
Trial Category:
Other Solid Tumor
Phase
II
Contact(s)
Location(s)
Southeast Nebraska Cancer Center, Lincoln, NE
This study is looking for patients who have been previously treated, and whose tumor has very specific mutations that are thought to respond to the drug Olaparib.
